Sign Out
Pharmacokinetic drug interactions involving CYP450 are not expected (see Pharmacology: Pharmacokinetics under Actions).
Co-administration of Firazyr with angiotensin-converting-enzyme (ACE) inhibitors has not been studied. ACE inhibitors are contraindicated in HAE patients due to possible enhancement of bradykinin levels.
